Viemed 10-Q Details Record Q3: $80.7M Revenue, $4.6M Net Income, $9.7M Cash
VMD sits 66% above its 52-week low of $6.05.
Summary
Viemed's Q3 10-Q confirms record $80.7 million revenue and $4.6 million net income, with cash down to $9.7 million after heavy equipment capex, buybacks and debt paydown. A $2.2 million Medicare ventilator audit remains under appeal with no accrual.
Key Events · Earnings and Guidance · VMD
-
Record Q3 Revenue and Profit
Q3 revenue was $80.673 million, up 12.2% from $71.914 million a year earlier, with net income attributable to Viemed of $4.638 million ($0.11 diluted EPS) versus $3.513 million.
-
Cash Fell Despite Strong Operating Flow
Cash and equivalents dropped to $9.676 million from $13.501 million at December 31, 2025, even though nine-month operating cash flow was $35.460 million; outflows included $23.788 million of property and equipment purchases, $7.738 million of buybacks and $7.558 million of term loan principal payments.
-
Medicare Ventilator Audit Still Open
The Qlarant/CMS audit's asserted overpayment was reduced to about $2.2 million from $5.9 million; Viemed appealed to the Medicare Appeals Council in August 2026 and has recorded no accrual, estimating a reasonably possible loss of zero to $2.2 million.
-
Debt Paydown Continued After Quarter
On October 29, 2026 the company repaid $2.0 million of its 2022 Term Loan Facility, cutting the balance from $5.3 million to $3.3 million; the $30 million revolver was undrawn at September 30, 2026.
Analysis · VMD · Industrial Applications And Services
The headline Q3 numbers were already out via this morning's 8-K, but the 10-Q is where the balance sheet and cash story live. Cash fell to $9.7 million from $13.5 million at year-end even as nine-month operating cash flow reached $35.5 million, because the company spent $23.8 million on rental equipment, $7.7 million buying back stock and $7.6 million paying down term debt. That leaves thin absolute liquidity against a $30 million revolver that is undrawn, so the cushion is the credit line, not the bank account. The Medicare ventilator audit is the item to track: the asserted overpayment is down to about $2.2 million from $5.9 million and sits with the Medicare Appeals Council, with no accrual booked.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VMD was trading at $10.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $385.1M. The 52-week trading range was $6.05 to $12.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.